Methods of using PD-L1 expression in treatment decisions for cancer therapy
US11353459B2 · kind B2 · utility
0Cited by
1References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 14, 2017 |
| Grant date | Jun 7, 2022 |
| Priority date | — |
| Expiry date | Apr 29, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70532
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on assaying one or more of circulating tumor cells (CTCs), epithelial to mesenchymal transition CTCs (EMTCTCs), cancer associated macrophage-like cells (CAMLs), and cancer associated vascular endothelial cells (CAVEs) isolated from a subject having cancer for PD-L1 expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.